Objective:To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms.Methods:C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously,then divided into 5 groups(14 per group),and treated with oxysophoridine(50,100,or 150 mg/kg) or cisplatin(4 mg/kg) for 10 days.Inhibitory rate of tumor,body weight gain,and influence indices on internal organs(liver,spleen and thymus) were evaluated.The differentially expressed genes between the oxysophoridine-treated group,and the control group were analyzed using cDNA microarray and quantitative real-time PCR(qRT-PCR) experiments.Results:Compared with the tumor weight of the control group(2.75±0.66 g),oxysophoridine significantly suppressed hepatocellular carcinoma growth in mice(P<0.01),with 0.82±0.36 g,0.57±0.22 g,and 1.22±0.67 g for the tumor weight in the low,moderate,and high dose treatment group, respectively.The moderate dose led to the highest inhibitory rate,79.3%.Observation of body weight gain and influence on three organs showed that compared with cisplatin,oxysophoridine produced fewer side effects in vivo.cDNA microarray and qRT-PCR showed that the most significant differentially expressed genes in the tumor samples of oxysophoridine-treated mice were mostly involved in regulating apoptosis,with the Tnfrsf11b (osteoprotegerin) gene being the most significantly affected.Conclusion:Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma,and its anti-hepatoma effect was probably related to osteoprotegerin activation. Objective: To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms. Methods: C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously, then divided into 5 groups (14 per group), and treated with oxysophoridine (50, 100, or 150 mg / kg) or cisplatin (4 mg / kg) for 10 days. Inhibitory rate of tumor, body weight gain, and influence indices on internal organs (liver, spleen and thymus) between the oxysophoridine-treated group, and the control group were analyzed using cDNA microarray and quantitative real-time PCR (qRT-PCR) experiments. Results: Compared with the tumor weight of the control group (2.75 ± 0.66 g), oxysophoridine significantly suppressed respectively, with 0.82 ± 0.36 g, 0.57 ± 0.22 g, and 1.22 ± 0.67 g for the tumor weight in the low, moderate, and high dose treatment groups, respectively. The moderate dose led to the highest inhibitory rate, 79.3 %. Observation of body weight gain and influence on three organs showed that compared with cisplatin, oxysophoridine produced fewer side effects in vivo. CDNA microarray and qRT-PCR showed that the most significant differentially expressed genes in the tumor samples of oxysophoridine-treated mice were mostly involved in regulating apoptosis, with the Tnfrsfllb (osteoprotegerin) gene being the most significantly affected. Conflux: Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma, and its anti-hepatoma effect was probably related to osteoprotegerin activation.